# Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery

> **NCT00003744** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 16 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00003744
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-11
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003744, "Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00003744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*